AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27524193
Drug: Four-channel FES
RxNorm normalized name: Channel catfish
DrugBank: Channel catfish (DB15548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-channel FES treatment based on normal gait pattern
Trial: 27524193
Drug: Single-channel FES
RxNorm normalized name: Channel catfish
DrugBank: Channel catfish (DB15548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-channel FES treatment
Trial: 20089454
Drug: N-acetyl-cysteine (NAC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetyl-cysteine (NAC) 1.2 g/d for 5 days starting at day 3 of the cycle for 12 consecutive cycles
Trial: 10372705
Drug: MK-677 (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-677 (25 mg daily for 8 weeks)
Trial: 8879912
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy for bulimia nervosa
Trial: 7048929
Drug: Short course
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short course of ampicillin (three doses)
Trial: 22314392
Drug: Amitriptyline (exact
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (exact dosage and duration not specified)
Trial: 16919533
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of telmisartan and nisoldipine
Trial: 11777359
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of oral prednisone per day
Trial: 2764533
Drug: Oral neomycin-erythromycin
RxNorm normalized name: erythromycin Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral neomycin-erythromycin
Trial: 31564410
Drug: [11C]telmisartan with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: [11C]telmisartan with predosing of 80 mg telmisartan (two 40 mg Micardis® tablets)
Trial: 31564410
Drug: [11C]telmisartan with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: [11C]telmisartan with predosing of 80 mg telmisartan
Trial: 23758821
Drug: Corifollitropin alfa
RxNorm normalized name: corifollitropin alfa
DrugBank: Corifollitropin alfa (DB09066)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Corifollitropin alfa or rFSH treatment flexibility options
Trial: 23758821
Drug: Receiving rFSH
RxNorm normalized name: rFSH-alpha
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Receiving rFSH on the day of hCG administration
Trial: 23758821
Drug: Reduced versus
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced versus fixed-dose of rFSH from day 8
Trial: 11359224
Drug: 15 mL
RxNorm normalized name: ethanol 0.15 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mL NS x 1 (n = 10)
Trial: 11359224
Drug: 15 mL
RxNorm normalized name: ethanol 0.15 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mL NS x 2 (n = 12)
Trial: 7524278
Drug: non-steroidal symptomatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: non-steroidal symptomatic treatment
Trial: 3063290
Drug: Active vitamin
RxNorm normalized name: OCTOCRYLENE 70 mg in 1 mL / HOMOSALATE 50 mg in 1 mL / OCTISALATE 50 mg in 1 mL / AVOBENZONE 30 mg in 1 mL TOPICAL CREAM [Garnier SkinActive Vitamin(E) C UV Brightening Daily Broad Spectrum SPF 30]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active vitamin D (alphacalcidol), 1 microgram daily
Trial: 21235416
Drug: Korean red
RxNorm normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Korean red ginseng (KRG) 3 g/day
Trial: 18698316
Drug: Betahistine 48
RxNorm normalized name: betahistine
DrugBank: Betahistine (DB06698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betahistine 48 mg (n=23)
Trial: 17070197
Drug: Evaluation while
RxNorm normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evaluation while off any estrogen therapy
Trial: 17070197
Drug: Physiologic transdermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiologic transdermal E(2) therapy
Trial: 12590030
Drug: Once-daily tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily tramadol tablets 150 mg
Trial: 12590030
Drug: Once-daily tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily tramadol tablets 200 mg
Trial: 12590030
Drug: Normal release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal release tramadol capsules 50 mg 8-hourly
Trial: 1441953
Drug: Continuous irrigation
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous irrigation with Ringer solution during cement curing
Trial: 3913478
Drug: Mianserin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mianserin (30 mg)
Trial: 3913478
Drug: Amitryptiline (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitryptiline (75 mg)
Trial: 19200421
Drug: Lamotrigine (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamotrigine (titrated to 200 mg/d)
Trial: 19796716
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate tablets providing elemental calcium at 63 mg/day
Trial: 19796716
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate tablets providing elemental calcium at 354 mg/day
Trial: 19796716
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate tablets providing elemental calcium at 660 mg/day
Trial: 19796716
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate tablets providing elemental calcium at 966 mg/day
Trial: 17460023
Drug: Fluconazole prophylaxis
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluconazole prophylaxis (6 mg/kg for 3 weeks, administered orally when enteral feeding achieved)
Trial: 8832526
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy including prednisone plus interferon (3 Mu/day induction, 3 Mu three times a week maintenance)
Trial: 2076622
Drug: naproxen gel
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: naproxen gel (10%)
Trial: 2076622
Drug: placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo gel (base alone)
Trial: 6195240
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g cephaloridine
Trial: 31621150
Drug: Oral tofacitinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tofacitinib (TOFA)
Trial: 30982549
Drug: Early-generation drug-eluting
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early-generation drug-eluting stents (DES)
Trial: 21538537
Drug: Quetiapine XR
RxNorm normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quetiapine XR (extended-release) at doses of 50-300 mg/day
Trial: 21538537
Drug: Quetiapine IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine IR (immediate-release) at doses of 25-300 mg/day
Trial: 19279424
Drug: Topical 0.2
RxNorm normalized name: coal tar topical 0.2% topical soap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.2 percent glyceryl trinitrate (GTN) ointment
Trial: 7547098
Drug: Tenidap sodium
RxNorm normalized name: tenidap sodium
DrugBank: Tenidap (DB13481)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenidap sodium 120 mg
Trial: 2262646
Drug: Salbutamol (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (0.2 mg, four times a day) and inhaled beclomethasone dipropionate (BDP, 0.5 mg, four times a day)
Trial: 2262646
Drug: Salbutamol (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (0.2 mg, four times a day)
Trial: 29158665
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of MB12066 (10, 30, 100, 150, 200, 300, or 400 mg)
Trial: 29158665
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of MB12066 (100 or 200 mg)
Trial: 24074269
Drug: 12-month lifestyle
RxNorm normalized name: moth bean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-month lifestyle intervention consisting of weekly group participation for six months on nutrition, physical activity, and lifestyle changes, followed by monthly group participation for an additional six months and individual monthly contacts from facilitators during the second six-month phase.
Trial: 10390399
Drug: Chloroquine (CQ),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine (CQ), 250 mg/d (Maintenance group)
Trial: 1991440
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E 1200 mg
Trial: 1991440
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E 600 mg
Trial: 29510792
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment arms (AZT, CPAP, AZT plus CPAP)
Trial: 22894725
Drug: Pre-bronchodilator FEV₁
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-bronchodilator FEV₁
Trial: 22894725
Drug: Post-bronchodilator FEV₁
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-bronchodilator FEV₁
Trial: 17662571
Drug: Lamotrigine (200,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamotrigine (200, 300, or 400 mg daily)
Trial: 29621901
Drug: Lamotrigine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamotrigine (up to 400 mg/day)
Trial: 10220625
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg TNK-tPA
Trial: 10220625
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg TNK-tPA
Trial: 10220625
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg TNK-tPA
Trial: 10220625
Drug: Overall (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall (30 to 50 mg TNK-tPA)
Trial: 10220625
Drug: Patients treated
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients treated within 6 hours after symptom onset (30 mg TNK-tPA)
Trial: 10220625
Drug: Patients treated
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients treated within 6 hours after symptom onset (40 mg TNK-tPA)
Trial: 25384080
Drug: High-dose oxytocin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose oxytocin (6 mU/min with increments every 45 min)
Trial: 25384080
Drug: Intermediate-dose oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermediate-dose oxytocin (3 mU/min with increments every 45 min)
Trial: 25384080
Drug: High-dose oxytocin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose oxytocin (6 mU/min with increments every 45 min) in nulliparous women
Trial: 25384080
Drug: Intermediate-dose oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermediate-dose oxytocin (3 mU/min with increments every 45 min) in nulliparous women
Trial: 25384080
Drug: High-dose oxytocin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose oxytocin (6 mU/min with increments every 45 min) in multiparous women
Trial: 25384080
Drug: Intermediate-dose oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermediate-dose oxytocin (3 mU/min with increments every 45 min) in multiparous women
Trial: 21884018
Drug: Accelerated infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Accelerated infusion of streptokinase (1.5 MU/20 min)
Trial: 21884018
Drug: Conventional infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional infusion of streptokinase (1.5 MU/60 min)
Trial: 17310863
Drug: 4.5 mg
RxNorm normalized name: phenol 14.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.5 mg per day of mirtazapine
Trial: 17310863
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg per day of mirtazapine
Trial: 15699486
Drug: anti-CD3 monoclonal
RxNorm normalized name: Anti-CD3
DrugBank: Muromonab (DB00075)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-CD3 monoclonal antibody (hOKT3gamma1(Ala‐Ala))
Trial: 9875725
Drug: Ketanserin (serotonin-2A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin (serotonin-2A antagonist)
Trial: 9875725
Drug: Risperidone (atypical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (atypical antipsychotic)
Trial: 9875725
Drug: Haloperidol (dopamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (dopamine antagonist, typical antipsychotic)
Trial: 7978432
Drug: IV propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV propofol (1-2 mg/kg) followed by a propofol infusion (75-100 micrograms.kg-1.min-1)
Trial: 7978432
Drug: IV thiopental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV thiopental (1-3 mg/kg) followed by a pentobarbital bolus (2-3 mg/kg)
Trial: 2558622
Drug: Cicletanine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cicletanine (100 mg/day)
Trial: 2558622
Drug: Cicletanine-enalapril combination
RxNorm normalized name: cicletanine
DrugBank: Cicletanine (DB12766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cicletanine-enalapril combination (100 mg/day cicletanine + 20 mg/day enalapril)
Trial: 18642654
Drug: Hypofractionated CyberKnife
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypofractionated CyberKnife stereotactic radiosurgery (CKSRS) with a marginal dose of 1800-2000 cGy/3 fractions, 80 to 89% isodose line (mean 83%), mean 97.9% tumor coverage.
Trial: 17135615
Drug: High-dose exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose exercise group (40 minutes per day of aerobic exercise)
Trial: 17135615
Drug: Low-dose exercise
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose exercise group (20 minutes per day of aerobic exercise)
Trial: 17135615
Drug: High-dose exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose exercise group
Trial: 12653876
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (anthropometric measures, insulin, HDL- and LDL-cholesterol)
Trial: 10732887
Drug: Medical Treatment
RxNorm normalized name: Medical air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical Treatment
Trial: 3903572
Drug: Terbutaline (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline (1 mg) administered from pressurised aerosol through a nebuhaler
Trial: 3903572
Drug: Terbutaline (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline (4 mg) as nebulised solution
Trial: 31442335
Drug: Terbutaline (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline (8 x 0.5 mg daily)
Trial: 27025829
Drug: Clindamycin 300
RxNorm normalized name: clindamycin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin 300 mg 4 times daily for 7 days
Trial: 27025829
Drug: TMP-SMX 320
RxNorm normalized name: sulfamethoxazole
DrugBank: Sulfamethoxazole (DB01015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TMP-SMX 320 mg/1600 mg twice daily for 7 days
Trial: 24942540
Drug: Subcutaneous tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous tocilizumab (TCZ‐SC) 162 mg every other week
Trial: 24942540
Drug: Subcutaneous placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous placebo (PBO‐SC) every other week
Trial: 22389077
Drug: d‐methamphetamine (0.42
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d‐methamphetamine (0.42 mg/kg)
Trial: 11136839
Drug: G-CSF (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF (5 microg/kg per day)
Trial: 11136839
Drug: Control (antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (antibiotics ceftazidime and amikacin without G-CSF)
Trial: 9847275
Drug: Tidal volume
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tidal volume (VT) below 10 ml/kg of body weight
Trial: 9847275
Drug: Conventional ventilatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional ventilatory approach with VT at 10 ml/kg or above
Trial: 8026282
Drug: Diet plus
RxNorm normalized name: Glucomannan/Grapefruit Extract/Pyridoxine Oral Tablet [GRAPEFRUIT DIET PLUS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet plus twice daily insulin
Trial: 2511683
Drug: Prolonged low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prolonged low-dose intravenous nitroglycerin
Trial: 53654
Drug: Single and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single and multiple agent chemotherapy
Trial: 53654
Drug: No immediate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No immediate treatment
Trial: 31150799
Drug: Statin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin treatment prescribed after baseline visit
Trial: 31150799
Drug: Oral fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fat tolerance test (OFTT) meal ingestion
Trial: 30177026
Drug: Artichoke leaf
RxNorm normalized name: artichoke leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artichoke leaf extract (ALE) 1800 mg/d (four tablets) for 12 weeks
Trial: 23163141
Drug: SQNYPBF (Shenmai
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQNYPBF (Shenmai Injection and Sulfotanshinone Sodium Injection, intravenously dripped once daily for 7 days)
Trial: 23163141
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (routine therapies including anti-infection, nutrition support, and glucose control with insulin pump)
Trial: 21209497
Drug: Combined drug
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined drug therapy/rtACS (D/ACS)
Trial: 21209497
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group D (conventional drug therapy)
Trial: 16675000
Drug: Aspirin 300
RxNorm normalized name: aspirin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 300 mg/day for 2 weeks
Trial: 12021952
Drug: Riluzole 50
RxNorm normalized name: riluzole 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riluzole 50 mg b.i.d.
Trial: 6113353
Drug: Intravenous acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous acyclovir (7-day course)
Trial: 25012804
Drug: Laparoscopic magnetic
RxNorm normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Laparoscopic magnetic sphincter augmentation (MSA)
Trial: 30031018
Drug: Double-dose proton
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-dose proton pump inhibitors (BID PPI)
Trial: 28424223
Drug: Low-dose DCB
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose DCB (2-µg/mm2 surface dose of paclitaxel)
Trial: 28424223
Drug: Low-dose DCB
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose DCB
Trial: 24650952
Drug: Lixisenatide 20
RxNorm normalized name: lixisenatide 20 mcg/0.2 mL subcutaneous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lixisenatide 20 μg once-daily for 24 weeks
Trial: 24650952
Drug: Lixisenatide 20
RxNorm normalized name: lixisenatide 20 mcg/0.2 mL subcutaneous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lixisenatide 20 μg once-daily
Trial: 19793585
Drug: Cocoa butter
RxNorm normalized name: Cocoa Butter
DrugBank: Cocoa butter (DB11086)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocoa butter cream
Trial: 17686445
Drug: Cisplatin/Gemcitabine therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin/Gemcitabine therapy
Trial: 15848611
Drug: CsA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CsA treatment with FF genotype
Trial: 15848611
Drug: CsA and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CsA and Tac treatment
Trial: 15848611
Drug: CsA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CsA treatment with BB genotype